Cargando…
Safety and effectiveness of a novel neuroprotectant, KUS121, in patients with non-arteritic central retinal artery occlusion: An open-label, non-randomized, first-in-humans, phase 1/2 trial
Kyoto University Substance (KUS) 121, an ATPase inhibitor of valosin-containing protein, is a novel neuroprotectant. We tested the safety and effectiveness of KUS121 in patients with acute central retinal artery occlusion (CRAO). We conducted an investigator-initiated, first-in-humans, phase 1/2 cli...
Autores principales: | Ikeda, Hanako Ohashi, Muraoka, Yuki, Hata, Masayuki, Sumi, Eriko, Ikeda, Takafumi, Nakagawa, Takayuki, Abe, Hiroyasu, Tada, Harue, Morita, Satoshi, Kakizuka, Akira, Yoshimura, Nagahisa, Tsujikawa, Akitaka |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7018138/ https://www.ncbi.nlm.nih.gov/pubmed/32053676 http://dx.doi.org/10.1371/journal.pone.0229068 |
Ejemplares similares
-
KUS121, an ATP regulator, mitigates chorioretinal pathologies in animal models of age-related macular degeneration
por: Muraoka, Yuki, et al.
Publicado: (2018) -
Neuoroprotective efficacies by KUS121, a VCP modulator, on animal models of retinal degeneration
por: Hasegawa, Tomoko, et al.
Publicado: (2016) -
KUS121 attenuates the progression of monosodium iodoacetate-induced osteoarthritis in rats
por: Iwai, Sachiko, et al.
Publicado: (2021) -
KUS121, a VCP modulator, attenuates ischemic retinal cell death via suppressing endoplasmic reticulum stress
por: Hata, Masayuki, et al.
Publicado: (2017) -
A VCP modulator, KUS121, as a promising therapeutic agent for post-traumatic osteoarthritis
por: Saito, Motoo, et al.
Publicado: (2020)